Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010077292) PREGNENOLONE SULFATE FOR THE TREATMENT OF NEUROLOGIC DISORDERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/077292 International Application No.: PCT/US2009/006473
Publication Date: 08.07.2010 International Filing Date: 09.12.2009
IPC:
A61K 31/56 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Applicants:
KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER [SA/SA]; P.O. Box 3354 Riyadh, 11211, MBC -03, SA (AllExceptUS)
ADRA, Chaker, N. [US/US]; US (UsOnly)
Inventors:
ADRA, Chaker, N.; US
Agent:
EL-HAYEK, Roque; Wolf, Greenfield & Sacks, P.C. Federal Reserve Plaza 600 Atlantic Avenue Boston, MA 02210-2206, US
Priority Data:
61/201,27509.12.2008US
Title (EN) PREGNENOLONE SULFATE FOR THE TREATMENT OF NEUROLOGIC DISORDERS
(FR) SULFATE DE PRÉGNÉNOLONE POUR LE TRAITEMENT D'AFFECTIONS NEUROLOGIQUES
Abstract:
(EN) The disclosure relates, in part, to methods of using pregnenolone sulfate (PREGS) to protect against the neurotoxicity of the β-amyloid peptide Aβ1-42. The disclosure also provides methods of using pegnanolone sulfate for treating neurologic disease or dysfunction. The disclosure further provides of using pegnanolone sulfate methods for stimulating or promoting growth of a neuronal cell.
(FR) La présente invention concerne en partie des procédés faisant intervenir du sulfate de prégnénolone (PREGS) pour protéger contre la neurotoxicité du peptide β-amyloïde aβ1-42. L'invention concerne également des procédés faisant intervenir le sulfate de prégnénolone pour traiter une maladie ou un dysfonctionnement neurologique. L'invention concerne en outre l'utilisation de procédés fondés sur le sulfate de prégnénolone pour stimuler ou favoriser le développement d'une cellule neuronale.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP2403501CN102625703CA2783331